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Antibodies rationally designed against staphylococcal virulence signals inhibit the development
of experimental disease by passive immunization [1], indicating great potential for therapeutic
approaches against staphylococcal and other bacterial infections.Infections with Staphylococcus aureus
are on a dangerous rise. While these
bacteria have threatened hospitalized
patients and individuals with predis-
posed risk factors for a long time,
and more than any other bacterial
pathogen, we are now facing hypervir-
ulent strains of Staph that are attack-
ing healthy people outside health care
settings [2]. Similar to the majority of
hospital-associated strains, these
strains carry methicillin resistance
(methicillin-resitant S. aureus or
‘‘MRSA’’), which makes treatment
with methicillin-type antibiotics impos-
sible. Already, the majority of all skin
and soft tissue infections reporting to
the emergency departments of U.S.
hospitals are due to this so-called
community-associated MRSA (CA-
MRSA) [3] and there is a great danger
that the acquisition of even more resis-
tance factors by CA-MRSA strains will
result in a public health catastrophe.
Therefore, there is an urgent need for
the development of novel anti-staph-
ylococcal therapeutics. Due to the
multiple antibiotic resistance found in
Staph and many other bacteria, some
researchers have proposed targeting
bacterial virulence instead of essential
genes, thus only attacking the expres-
sion of harmful molecules while leaving
the bacteria alive [4]. This approach
is believed to minimize the develop-
ment of resistance. However, both
drug and vaccine development for
staphylococcal infections is extremely
difficult owing to a pronounced func-
tional redundancy of virulence deter-
minants. Thus, finding a way to elimi-
nate several virulence determinants at
the same time has become a major
goal in these endeavors. For example,
inhibition of the enzyme that catalyzesthe anchoring of surface enzymes to
the staphylococcal cell wall—proteins
of extreme importance for the estab-
lishment of an infection—would elimi-
nate a series of virulence determinants
of similar function [5].
Specifically, global regulators of
virulence have been in the focus of
virulence-targeted approaches to find
novel drugs, not only in staphylococci,
but in many bacterial pathogens. The
best studied and probably most im-
portant virulence regulator in staphylo-
cocci is the accessory gene regulator
agr, which has been investigated in de-
tail in the laboratory of Richard Novick
at New York University. This system
is responsible for adapting bacterial
physiology and virulence factor ex-
pression to changing environmental
conditions, dependent on the density
of the bacterial population [6]. Except
for a certain eclipse phase, the activ-
ity of agr increases with the size of
the bacterial population during infec-
tion, which has been shown using
in vivo expression studies [7]. Notably,
Dr. Novick and coworkers, together
with other groups including ours, have
found that agr signals through an ex-
ported autoinducing peptide (AIP),
whose overall structure is conserved,
but whose amino acid sequence dif-
fers between subgroups [8, 9]. Im-
portantly, AIPs from different origins
have the common feature of inhibiting
agr expression in nonrelated groups,
thereby preventing expression of a se-
ries of important virulence factors
[8, 10]. In fact, it has been shown that
the administration of an inhibiting AIP
together with an infectious strain leads
to a significant reduction in S. aureus
infectivity in a mouse subcutaneous
infection model [8].Chemistry & Biology 14, October 2007 ª2However, a major drawback of the
crossinhibiting AIP-based strategy for
the prevention of staphylococcal dis-
eases is the relative instability of the
unusual thiolactone ring structure of
staphylococcal AIPs. Therefore, sys-
temic application of crossinhibiting
AIPs has so far not been successful
and the development of quorum-sens-
ing inhibitors for therapeutic use has
not been pursued with the same in-
tensity as in Gram-negative bacteria
(which use chemically different signals
such as the homoserine lactones) [11].
Therapeutic use of AIPs would only be
possible if one were to find a molecule
that combines agr inhibiting features
with significantly improved stability.
Now, as an elegant alternative to
overcome the AIP instability problem,
Park et al. [1] report on the use of
anti-AIP antibodies to inhibit agr func-
tion (Figure 1). In this issue of Chemis-
try & Biology, they show that anti-
bodies rationally designed against the
AIP of one S. aureus agr subgroup
specifically prevent agr expression
and S. aureus disease in an animal
model of abscess formation. Notably,
the antibodies also provided protec-
tion when used for passive immuniza-
tion, i.e., when given before infection.
These findings take the research on
anti-agr drugs to a new level and in-
crease our hope that we may one day
successfully target this key staphylo-
coccal virulence regulator to control
infection. While the general applicabil-
ity of the presented approach will need
to be shown for all S. aureus agr sub-
types, especially for type 1 (the most
prevalent among MRSA), it appears
that the anti-AIP antibodies have very
good chances to be of general use.
Likely, a broader spectrum S. aureus007 Elsevier Ltd All rights reserved 1093
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PreviewsFigure 1. Inhibition of Quorum-Sensing Controlled Virulence Determinants by
Antibodies against the Staphylococcus aureus agr Signal
The agr quorum-sensing regulator controls the expression of virulence determinants in a cell
density-dependent fashion via secretion of an extracellular signaling peptide (autoinducing pep-
tide, AIP). The AIP has a length of 7–9 amino acids, in which a conserved cysteine is linked to
the C terminus in a thiolactone, or rarely, lactone linkage. Toxins and other determinants of acute
virulence are under positive control by agr. Therefore, antibodies against the AIP block the devel-
opment of experimental acute disease, as shown in the report by Park et al. [1]. As agr controls
characteristic determinants of attachment and biofilm formation in an opposite fashion, the use
of such antibodies for the treatment of staphylococcal infections may, however, be limited to
specific types of infection.therapeutic based on anti-AIP anti-
bodies may easily be produced
against a mixture of AIPs of all four
S. aureus agr subgroups. Additionally,
as the sequences from a variety of
staphylococcal agr-type AIPs are
known and there are reports on agr-
type systems in other Gram-positive
bacteria, the same strategy may be
used for other staphylococcal and
even nonstaphylococcal pathogens.
Finally, to assess the chances of gen-
eral applicability for bacteria that use
the agr quorum-sensing system, it will
be of central interest to investigate
whether the conserved (thio)lactone
structure plays a key role in antigen-
antibody recognition, or whether this
interaction is mainly determined by
the primary amino acid sequence of
the AIP hapten.
However, there are some limitations
and questions that first need to be
addressed before an anti-AIP antibody
will be suitable for the treatment of
disease. Most importantly, inhibiting
the agr regulator in staphylococci not
only leads to the downregulation, but1094 Chemistry & Biology 14, October 2also to the upregulation of several
virulence determinants that are under
opposite regulation by agr. For exam-
ple, the already mentioned surface
proteins that are involved in the estab-
lishment of an infection are for the
most part downregulated by agr [6].
Thus, inhibition of agr would lead to
their increased expression, the in vivo
outcome of which is not known. Fur-
ther, agr appears to regulate biofilm
formation in a negative fashion [12].
Biofilm formation, the agglomeration
of cells on a surface within a sticky ma-
trix, significantly lowers the efficacy of
antibiotics and innate host defense
mechanisms. Indeed, agr negative
mutants are isolated frequently from
sometimes severe types of biofilm-
associated staphylococcal infection
and constructed agr mutants show
increased colonization of indwelling
medical devices in experimental bio-
film-associated infection [12, 13].
We will have to find out whether
these facts may possibly limit the appli-
cability of agr-inhibiting drugs. How-
ever, the importance of agr in many007 ª2007 Elsevier Ltd All rights reservedstaphylococcal infections has been
demonstrated in vivo [7, 8]. Further-
more, strong expression of agr ap-
pears to be an important characteristic
of the dangerous CA-MRSA strains
[14]. Therefore, using agr as a target
with an improved strategy as de-
scribed by Park et al. [1], is an ex-
tremely promising novel attempt to
find anti-staphylococcal therapeutics
and control the increasing spread of S.
aureus and especially the CA-MRSA
epidemic.
REFERENCES
1. Park, J., Jagasia, R., Kaufmann, G.F.,
Mathison, J.C., Ruiz, D.I., Moss, J.A., Meij-
ler, M.M., Ulevitch, R.J., and Janda, K.D.
(2007). Chem. Biol. 14, this issue, 1119–
1127.
2. Chambers, H.F. (2005). N. Engl. J. Med.
352, 1485–1487.
3. Moran, G.J., Krishnadasan, A., Gorwitz,
R.J., Fosheim, G.E., McDougal, L.K.,
Carey, R.B., and Talan, D.A. (2006).
N. Engl. J. Med. 355, 666–674.
4. Alksne, L.E., and Projan, S.J. (2000). Curr.
Opin. Biotechnol. 11, 625–636.
5. Mazmanian, S.K., Liu, G., Ton-That, H.,
and Schneewind, O. (1999). Science 285,
760–763.
6. Novick, R.P. (2003). Mol. Microbiol. 48,
1429–1449.
7. Wright, J.S., 3rd, Jin, R., and Novick, R.P.
(2005). Proc. Natl. Acad. Sci. USA 102,
1691–1696.
8. Ji, G., Beavis, R., and Novick, R.P. (1997).
Science 276, 2027–2030.
9. Otto, M., Sussmuth, R., Jung, G., and
Gotz, F. (1998). FEBS Lett. 424, 89–94.
10. Otto, M., Sussmuth, R., Vuong, C., Jung,
G., and Gotz, F. (1999). FEBS Lett. 450,
257–262.
11. Otto, M. (2004). FEMS Microbiol. Lett. 241,
135–141.
12. Vuong, C., Saenz, H.L., Gotz, F., and Otto,
M. (2000). J. Infect. Dis. 182, 1688–1693.
13. Vuong, C., Kocianova, S., Yao, Y., Car-
mody, A.B., and Otto, M. (2004). J. Infect.
Dis. 190, 1498–1505.
14. Wang, R., Braughton, K.R., Kretschmer,
D., Bach, T.L., Queck, S.Y., Li, M., Ken-
nedy, A.D., Dorward, D.W., Klebanoff,
S.J., Peschel, A., et al. (2007). Nat.
Med., in press.
